Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 1Phase 1 1

Status

Completed 2Terminated 1Recruiting 1Not yet recruiting 1

Sponsor Class

INDUSTRY 5

Study Type

Interventional 5

Sponsor

Cancer Type

Thoracic 5Head & Neck 1Gynecologic 1Breast 1

Conditions

Breast Neoplasms 8Lymphoma, Mantle-Cell 6Lymphoma, Large B-Cell, Diffuse 6Lymphoma 6Burkitt Lymphoma 6Small Cell Lung Carcinoma 5Lymphoma, T-Cell 4Lymphoma, Follicular 4Waldenstrom Macroglobulinemia 3Ovarian Neoplasms 3Neuroblastoma 3Lymphoma, Large-Cell, Anaplastic 3Lymphoma, B-Cell, Marginal Zone 3Lymphoma, B-Cell 3Leukemia, Myeloid, Acute 3Immunoblastic Lymphadenopathy 3Head and Neck Neoplasms 3Triple Negative Breast Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Prostatic Neoplasms 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Pancreatic Neoplasms 2Multiple Myeloma 2Lymphoma, Non-Hodgkin 2Lung Neoplasms 2Leukemia, Lymphocytic, Chronic, B-Cell 2Hodgkin Disease 2Gastrointestinal Neoplasms 2Carcinoma, Non-Small-Cell Lung 2

Interventions

Etoposide 154Carboplatin 142Cisplatin 104Topotecan 74durvalumab 48atezolizumab 46Irinotecan 44pembrolizumab 39Paclitaxel 34Nivolumab 33Radiotherapy 29anlotinib 23PM 01183 22Gemcitabine 21Drug Therapy 20apatinib 19Ipilimumab 18Docetaxel 17Temozolomide 16Platinum 16Radiosurgery 15Pemetrexed 14toripalimab 13tislelizumab 13olaparib 13Bevacizumab 13amrubicin 11Magnetic Resonance Spectroscopy 11Cyclophosphamide 11rovalpituzumab tesirine 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Interventional × Small Cell Lung Carcinoma × MLN 8237 × Clear all
NCT06095505 2026-06-05

ALISCA-Lung1

Puma Biotechnology, Inc.

Phase 2 Recruiting
120 enrolled
Thoracic

Small Cell Lung Carcinoma

NCT07465757 2026-03-12

ALISCA-Lung2

Puma Biotechnology, Inc.

Phase 2 Not yet recruiting
50 enrolled
Thoracic

Small Cell Lung Carcinoma

NCT02367352 2019-06-26

Alisertib (MLN8237) in Combination With Weekly Paclitaxel in East Asian Patients With Advanced Solid Tumors

Takeda

Phase 1 Terminated
9 enrolled 14 charts
GynecologicThoracic

Ovarian Neoplasms, Small Cell Lung Carcinoma

NCT02038647 2018-12-27

Phase 2 Study of Alisertib (MLN8237) in Combination With Paclitaxel Versus Placebo in Combination With Paclitaxel as Second Line Therapy for Small Cell Lung Cancer (SCLC)

Takeda

Phase 2 Completed
178 enrolled 27 charts
Thoracic

Small Cell Lung Carcinoma

NCT01045421 2016-08-15

Alisertib in Adults With Nonhematological Malignancies, Followed by Alisertib in Lung, Breast, Head and Neck or Gastroesophageal Malignancies

Millennium Pharmaceuticals, Inc.

Phase 1/2 Completed
273 enrolled 28 charts
BreastHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡